MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
Advanced lung cancer has poor survival with few therapies. EGFR tyrosine kinase inhibitors (TKIs) have high response rates in patients with activating EGFR mutations, but acquired resistance is inevitable. Acquisition of the EGFR T790M mutation causes over 50% of resistance; MET amplification is als...
Main Authors: | Elena Ortiz-Zapater, Richard W Lee, William Owen, Gregory Weitsman, Gilbert Fruhwirth, Robert G Dunn, Michael J Neat, Frank McCaughan, Peter Parker, Tony Ng, George Santis |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5283661?pdf=render |
Similar Items
-
MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies
by: Patricia Martin Romano, et al.
Published: (2019-06-01) -
Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
Published: (2011-01-01) -
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01) -
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
by: T. L. Peters, et al.
Published: (2021-10-01) -
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
by: Susan L. Feldt, et al.
Published: (2023-05-01)